Profit

Expect 10% Upside In Claris Lifesciences: Nirmal Bang

PUBLISHED ON: December 16, 2016 | Duration: 5 min, 30 sec

  
loading..
Vishal Manchanda, research analyst at Nirmal Bang Securities, says Claris Lifesciences would have around Rs 3,000 crore cash on its book once all the cash from the Baxter deal is received. The company would most likely distribute 80 per cent of the cash to shareholders, he adds.
ALSO WATCH
Buy Lumax Auto Technologies: Mehraboon Irani

................................ Advertisement ................................

................................ Advertisement ................................